Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Adams

Showing results (91-100 of 207) with videos related to

Pageof 21
Sort By:
International Journal of Molecular Sciences|November 11, 2020
A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T LymphocytesSun-Hye Shin, Hee-Yeon Kim, Hee-Soo Yoon, et al.
The Biochemical Journal|April 26, 2008
Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKsTian-Rui Xu, George S Baillie, Narinder Bhari, et al.
Journal of Medicinal Chemistry|March 20, 2019
Topographical Mapping of Isoform-Selectivity Determinants for J-Channel-Binding Inhibitors of Sphingosine Kinases 1 and 2David R Adams, Salha Tawati, Giacomo Berretta, et al.
The Journal of Biological Chemistry|January 21, 2009
MEK1 binds directly to betaarrestin1, influencing both its phosphorylation by ERK and the timing of its isoprenaline-stimulated internalizationDong Meng, Martin J Lynch, Elaine Huston, et al.
Molecular Genetics & Genomic Medicine|November 7, 2020
DYRK1A pathogenic variants in two patients with syndromic intellectual disability and a review of the literatureLaura E Meissner, Ellen F Macnamara, Precilla D'Souza, et al.
Biochemical Pharmacology|March 12, 2013
Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)Ryan T Cameron, Ryan G Coleman, Jon P Day, et al.
Rare (Amsterdam, Netherlands)|February 24, 2025
Changes in glycosphingolipid levels in plasma and cerebrospinal fluid of individuals with Lysosomal Free Sialic Acid Storage DisorderMarya S Sabir, Lynne Wolfe, David R Adams, et al.
Experimental Dermatology|May 21, 2019
E-cadherin and p120ctn protein expression are lost in hidradenitis suppurativa lesionsAmanda M Nelson, Zhaoyuan Cong, Samantha L Gettle, et al.
BMC Genomics|January 26, 2024
LUSTR: a new customizable tool for calling genome-wide germline and somatic short tandem repeat variantsJinfeng Lu, Camilo Toro, David R Adams, et al.
Bioorganic & Medicinal Chemistry Letters|August 14, 2012
Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolonesKoji Ochiai, Satoshi Takita, Akihiko Kojima, et al.
Pageof 21

Showing results (91-100 of 207) with videos related to

Sort By:
Pageof 21
International Journal of Molecular Sciences|November 11, 2020
A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T LymphocytesSun-Hye Shin, Hee-Yeon Kim, Hee-Soo Yoon, et al.
The Biochemical Journal|April 26, 2008
Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKsTian-Rui Xu, George S Baillie, Narinder Bhari, et al.
Journal of Medicinal Chemistry|March 20, 2019
Topographical Mapping of Isoform-Selectivity Determinants for J-Channel-Binding Inhibitors of Sphingosine Kinases 1 and 2David R Adams, Salha Tawati, Giacomo Berretta, et al.
The Journal of Biological Chemistry|January 21, 2009
MEK1 binds directly to betaarrestin1, influencing both its phosphorylation by ERK and the timing of its isoprenaline-stimulated internalizationDong Meng, Martin J Lynch, Elaine Huston, et al.
Molecular Genetics & Genomic Medicine|November 7, 2020
DYRK1A pathogenic variants in two patients with syndromic intellectual disability and a review of the literatureLaura E Meissner, Ellen F Macnamara, Precilla D'Souza, et al.
Biochemical Pharmacology|March 12, 2013
Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)Ryan T Cameron, Ryan G Coleman, Jon P Day, et al.
Rare (Amsterdam, Netherlands)|February 24, 2025
Changes in glycosphingolipid levels in plasma and cerebrospinal fluid of individuals with Lysosomal Free Sialic Acid Storage DisorderMarya S Sabir, Lynne Wolfe, David R Adams, et al.
Experimental Dermatology|May 21, 2019
E-cadherin and p120ctn protein expression are lost in hidradenitis suppurativa lesionsAmanda M Nelson, Zhaoyuan Cong, Samantha L Gettle, et al.
BMC Genomics|January 26, 2024
LUSTR: a new customizable tool for calling genome-wide germline and somatic short tandem repeat variantsJinfeng Lu, Camilo Toro, David R Adams, et al.
Bioorganic & Medicinal Chemistry Letters|August 14, 2012
Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolonesKoji Ochiai, Satoshi Takita, Akihiko Kojima, et al.
Pageof 21